Proactive Investors - Run By Investors For Investors

Silence Therapeutics given access to genetic database in its bid to find new breakthrough treatments

Genomics England has whole sequencing data on 100,000 genomes
Silence Therapeutics given access to genetic database in its bid to find new breakthrough treatments
Code to life: a genome is an organism’s complete set of DNA, including all of its genes

Silence Therapeutics PLC (LON:SLN) has been given access to part of a genetic database as it bids to find treatments for rare diseases and ailments.

Genomics England has whole sequencing data on 100,000 genomes.

A genome is an organism’s complete set of DNA, including all of its genes. Each genome contains the information needed to build and maintain that organism.

It is the key to understanding how people differ genetically and therefore how they might respond to different medicines.

Data mining exercise 

In the case of Silence, an expert in silencing disease-associated genes, having access to the database will help in its drug development effort.

Under the terms of the deal with Genomics England, Silence will “data mine” a subset of the information to focus on rare diseases and cardio-metabolic illnesses.

It wants to find disease-modifying target genes best suited to its unique technology.

The exercise should also help with “patient stratification” (dividing them into groups and sub-groups) and recruitment as the company develops its RNAi product candidates.

“This key collaboration will help us increase innovation in our target gene choices and will also be attractive to potential partners as we explore a variety of business development opportunities," said Silence chief executive, Dr David Horn Solomon.

View full SLN profile View Profile

Silence Therapeutics PLC Timeline

Related Articles

1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use